

Clinical trials of rimonabant 20mg

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
rimonabant 20mg vs placebo			
RIO europe 20mg , 2005 n=599/305 follow-up:	rimonabant 20mg daily versus placebo	patients with body-mass index 30 kg/m ² or greater, or body-mass index greater than 27 kg/m ² with treated or untreated dyslipidaemia, hypertension, or both	Parallel groups Double blind Europe and USA
Rio-lipid 20 mg , 2005 n=346/342 follow-up: 12 months	rimonabant 20 mg daily versus placebo	overweight or obese patients (body-mass index 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men)	Parallel groups Double blind worldwide (8 countries)
RIO-North America 20 mg , 2006 [NCT00029861] n=1222/607 follow-up:	rimonabant 20mg daily versus placebo	obese (body mass index ≥ 30) or overweight (body mass index ≥ 27 and treated or untreated hypertension or dyslipidemia) adult patients	Parallel groups Double blind US and Canada
rimonabant 20mg vs rimonabant 5mg			
RIO europe (20 vs 5 mg) , 2005 n=599/603 follow-up:	-	-	-

More details and results :

- weight-loss drugs for cardiovascular prevention in overweight or obese patients at <http://www.trialresultscenter.org/go-Q444>

References

RIO europe 20mg, 2005:

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 Apr 16-22;365:1389-97 [[15836887](#)]

Rio-lipid 20 mg, 2005:

Despres JP, Golay A, Sjostrom L Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 Nov 17;353:2121-34 [16291982]

RIO-North America 20 mg, 2006:

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, , Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75. [16478899] [10.1001/jama.295.7.761](https://doi.org/10.1001/jama.295.7.761)

RIO europe (20 vs 5 mg), 2005:

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 Apr 16-22;365:1389-97 [15836887]

Entry terms: rimonabant, rimonabant, SR141716, SR 141716, Acomplia, Zimulti, SR 141716A, SR141716A, SR-141716A,